Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Clinical Trial of Innate Immunity Stimulation Via TLR9 in Early Alzheimer's Disease (AD)

NCT05606341 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT05606341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05606341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Clinical Trial of Innate Immunity Stimulation Via TLR9 in Early Alzheimer's Disease (AD)
Lead sponsor
NYU Langone Health
Phase
Phase 1
Overall status
Recruiting
Start date
March 13, 2023
Completion date
November 30, 2026
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer dementia, mild cognitive impairment